Please sign in to follow a disease.
Diffuse astrocytoma
MONDO:0016686A low-grade (WHO grade II) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified.
Also known as: WHO grade II astrocytoma, astrocytoma, diffuse, astrocytoma, diffuse, malignant, diffuse astrocytoma, grade II astrocytic neoplasm, grade II astrocytic tumor, grade II astrocytic tumour, grade II astrocytoma
1477 clinical trials for this condition and its sub-types, 25 tagged with Diffuse astrocytoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Diffuse astrocytoma
-
Fibrillary astrocytoma 3 trials
-
Gemistocytic astrocytoma 0 trials
-
Protoplasmic astrocytoma 0 trials
-
Can a nationwide charting of brain tumors reveal who is most affected?
Knowledge-focused Not yet recruitingThis study looks back at the medical records of 350 people in Brazil diagnosed with IDH-mutant diffuse glioma, a type of brain tumor, from 2021 onward. Researchers will collect information on age, race, income, education, and other factors to build a detailed picture of who gets …
Sponsor: Latin American Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New scan may reveal brain tumor drug effects in weeks, not years
Knowledge-focused Not yet recruitingThis study looks at whether a special PET scan (18F-AGX) can detect early changes in brain tumor activity in adults with slow-growing IDH-mutant gliomas who are taking the drug Vorasidenib. Ten participants will get the drug daily for about a year and have multiple PET and MRI sc…
Sponsor: Huashan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC